Atara Receives European Commission Approval for the First Ever Allogeneic T-Cell Immunotherapy.
Home hero


Cutting-edge science. A fresh approach.

Atara is an allogeneic T-cell immunotherapy company. We're harnessing the natural biology of T cells—our body’s most effective weapon in fighting disease—to develop transformative therapies for patients with cancer and autoimmune conditions.

    Off-the-shelf approach

    Allogeneic T-cell therapies can be readily available for rapid delivery within days.

    Scalable manufacturing

    Efficient, robust process with the ability to produce over a thousand doses from one healthy donor.

    Highly versatile platform

    Potential application for a wide range of disease-causing viral and non-viral targets.

We’re developing a pipeline of firsts.

Our investigational T-cell therapies target difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. We’re the first company ever to receive an approval for an allogeneic T-cell immunotherapy.

Dig deeper.

Explore patient stories, our clinical studies, or visit our investor hub for more information.